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The synovial fluid glycoprotein lubricin (also known as
proteoglycan 4) is a mucin-type O-linked glycosylated bio-
logical lubricant implicated to be involved in osteoarthritis
(OA) development. Lubricin’s ability to reduce friction is
related to its glycosylation consisting of sialylated and unsia-
lylated Tn-antigens and core 1 and core 2 structures. The
glycans on lubricin have also been suggested to be involved
in crosslinking and stabilization of the lubricating superficial
layer of cartilage by mediating interaction between lubricin
and galectin-3. However, with the spectrum of glycans being
found on lubricin, the glycan candidates involved in this
interaction were unknown. Here, we confirm that the core
2 O-linked glycans mediate this lubricin–galectin-3 inter-
action, shown by surface plasmon resonance data indicating
that recombinant lubricin (rhPRG4) devoid of core 2 struc-
tures did not bind to recombinant galectin-3. Conversely,
transfection of Chinese hamster ovary cells with the core 2
GlcNAc transferase acting on a mucin-type O-glycoprotein
displayed increased galectin-3 binding. Both the level of
galectin-3 and the galectin-3 interactions with synovial lubricin
were found to be decreased in late-stage OA patients, coinciding
with an increase in unsialylated core 1 O-glycans (T-antigens)
and Tn-antigens. These data suggest a defect in crosslinking of
surface-active molecules in OA and provide novel insights into
OAmolecular pathology.
Lubricin is a large glycoprotein that is found in synovial fluid
(SF). Lubricin is produced by articular chondrocytes and syno-
viocytes in the cartilage surface layer and secreted into the SF.
In healthy joints, lubricin molecules are bound to the surface of
articular cartilage, are chondroprotective, and provide lubrica-
tion at very low friction under high stress (1, 2). The lubricating
properties of lubricin are dependent, in part, on denseO-glyco-
sylation (3).
Lubricin, encoded by the Prg4 gene, has been associated with
pathological conditions in the joint tissue, with mutations in
Prg4 associated with camptodactyly-arthropathy-coxa vara-
pericarditis syndrome (4), a rare, arthritis-like autosomal reces-
sive disorder causing joint abnormalities. The lubrication prop-
erties of lubricin also suggest that the protein is associated with
arthritic diseases, because it has been proposed that defective
lubrication aggravates joint degradation (5). Osteoarthritis (OA)
is the most common arthritic disease, with high prevalence in
elderly people, and involves cartilage degradation in the articu-
lar joints, leading to pain and restricted motion (6). Boundary
lubrication of OA SF deficient in lubricin has been shown to be
lowered in in vitro experiments (7).
Different isoforms of lubricin are found throughout the
body. In addition to presence in SF and the boundary articular
cartilage, lubricin has also been detected in low amounts in
menisci, blood, urine, and tendons (8–12). A possible immuno-
logical role of lubricin has been suggested because it has been
shown to be involved in sepsis in a mouse model (13), being the
most up-regulated protein detected in hepatic tissue. Lubricin
is also associated with the plasmamembrane of human neutro-
phils (14), and a lubricating and protective function of lubricin
has been reported in ocular surfaces (15, 16).
The full-length isoform found in SF consists of 1,404 amino
acids (aa), equivalent to 150 kDa, but is;300 kDa when fully O-
glycosylated. The protein contains a central mucin domain con-
sisting of 59 imperfect repeats of the aa sequence EPAPTTPK,
where the threonine residues are potential sites for diverse and
dense O-glycosylation. Despite its gene name, it is not a typical
proteoglycan and has merely a single proposed glycosaminogly-
can site that may or may not be present/occupied (17). The
mucin domain is flanked by two somatomedin B-like domains
on the N-terminal side and a hemopexin domain on the C-termi-
nal side, domains which have been proposed to interact with
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extracellular matrix proteins such as cartilage oligomeric matrix
protein (COMP), collagen II, and fibronectin (18, 19). The glycans
on the lubricin mucin domain are the main contributors to its
molecular weight and are responsible for the lubricating function
of the molecule, attracting water to the superficial layer, and pro-
viding repulsive negative charges to the cartilage superficial layer
(20).
Recombinant human lubricin (rhPRG4) has been evaluated
for a large number of potential clinical applications as a fric-
tion-reducing lubricant on biological surfaces (16). Forms of
rhPRG4 have been investigated for use as an agent to prevent
abdominal adhesion, a treatment of bladder impermeability, a
lubricant supplement in contact lens hydrogels, and a thera-
peutic in patients suffering from dry eye disease (21–24). In a
rodent model, addition of lubricin has been shown to delay the
progression of OA (25). Intra-articular injections of rhPRG4
in guinea pigs (26) and Yucatan minipigs (26) with medial
meniscal destabilization, a model system for posttraumatic OA,
exhibited decreased cartilage damage and inflammation. Lubri-
cinmay therefore be a potential candidate for treatment of OA.
Galectins are glycan-binding proteins with many proposed
intra- and extracellular functions within cell regulation, the
immune system, and cancer progression (27). They bind a large
range of b-galactosides present on bothN- andO-linked glyco-
proteins, with binding affinity highly dependent on branching
and terminal residues (28). Galectin-3 has been shown to be
associated with chondrocytes and has been proposed to be
involved in OA pathogenesis (29, 30). It is unique among the
galectins because it is the only galectin that comprises a C-ter-
minal carbohydrate recognition domain linked to a nonlectin
N-terminal collagen-like domain, making it possible for galec-
tin-3 protein subunits to oligomerize (31, 32). In the joint,
galectin-3 and lubricin have been proposed to generate a com-
plex, stable lubricating network on the articular cartilage (33).
Limited studies have addressed galectin-3 binding toO-glycans.
Galectin-3 displays only a weak binding affinity to the T-anti-
gen (Galb1-3GalNAca1-) on synthetic MUC1 glycopeptides
(34, 35). The T-antigen is also highly abundant onO-glycans on
lubricin and has been proposed to be responsible for the inter-
action between galectin-3 and lubricin (33).
Because carbohydrates play such a crucial role in the func-
tion of lubricin, we decided to use state-of-the-art glycomic and
glycoproteomic analysis techniques to compare the different
glycoforms of synovial lubricin from OA patients and control
individuals and to compare these with rhPRG4 expressed in
CHO cells. We confirmed the presence of galectin-3 in SF and
explored differences in the binding of galectin-3 to the various
O-glycoforms. Our results enable us to correlate pathological
glycosylation changes in OA with a functionally defective su-
perficial layer and provide a pathway for recombinant lubricin
glyco-design for optimal galectin-3 binding.
Results
Decreased core 2 and sialylation on SF lubricin from OA
patients
Wewanted to determine whether changes inO-linked glyco-
sylation of synovial lubricin were associated with OA pathol-
ogy. Detailed quantitative analysis of the released O-glycans
was performed. Lubricin isolated from SF of controls (n = 7)
was compared with lubricin isolated from late-stage OA
patients (n = 7).O-linked oligosaccharides from lubricin in age-
and sex-matched OA patients’ and controls’ SF were released
by reductive b-elimination and analyzed with quantitative mul-
tiple reaction monitoring (MRM) on a QTRAP 6500 triple
quadrupole-linear ion trap hybrid mass spectrometer as has
been described in detail (36). TheMRMmethod was developed
to semi-quantify a range of 22 core 1, 2, and 3 glycans on native
lubricin from both controls and OA patients (36). We refer to
semi-quantification here because without the appropriate
standards, a technical difficulty of O-glycan research, absolute
quantification is not attained. This is because of differences in
ionization and stability between glycans, particularly between
charged and neutral glycans. MRM is able to mitigate some of
this because all glycan structures, even the sialic acid isomers,
are optimized for the conditions that allow for their best
quantification (36). Nevertheless, the most apt use of this
approach is to compare the same glycan or type of glycans
between samples.
Although the abundances of these glycans were found to dif-
fer between the two sample types, the glycan repertoire was the
same (Fig. 1, A and B and Table S1). A significant increase in
the unmodified core 1 structure (T-antigen) on lubricin iso-
lated from OA patients (40.41% 6 3.43% (mean 6 S.E.) of all
glycans, p = 0.0274) was detected compared with normal con-
trols (29.90% 6 3.10%). This increase in glycan truncation was
accompanied by a significant decrease in a range of lower abun-
dant core 2 structures, predominantly sialylated and sulfated
structures. There was an overall reduction in core 2 structures
in OA samples (4.67% 6 0.98%, p = 0.0288) compared with
control samples (9.11% 6 1.50%) and an increase in core 1
structures (OA, 94.85% 6 1.05% and control, 90.32% 6 1.47%;
p = 0.0275). Altogether, this resulted in a trend toward a reduc-
tion in charged structures, primarily because of a reduction in
core 2 structures, in the OA samples (57.16% 6 3.03%, p =
0.558) compared with the controls (66.51%6 3.21%). This indi-
cated that changes in O-glycosylation, specifically the loss of
core 2 structures that are predominately charged, is associated
with OA.
CHO-expressed rhPRG4 has mainly sialylated core 1 O-
glycans
Given the potential of rhPRG4 as a biopharmaceutical lubri-
cant, where the function relies on the O-linked glycosylation,
we analyzed the released glycans from CHO-expressed rhPRG4
to identify the presence of core 1 and core 2 glycans and sialyla-
tion and compare it to O-glycosylation of the native human SF
lubricin.
The composition ofO-glycans released from rhPRG4was an-
alyzed using the same MRM lubricin method as for native
human lubricin. These analyses were performed on two differ-
ent batches of rhPRG4, which revealed a composition of solely
core 1 structures (Fig. 1, C and D), the same core 1 structures
observed on human synovial lubricin (Fig. 1, A and B). The
most abundant oligosaccharide was the sialylated core 1
Galectin-3 and lubricin



























NeuAca2-3Galb1-3GalNAc structure, which made up 85% of
all glycans. A low proportion of neutral O-glycans (12% of all
glycans) and a higher amount of charged glycans (88% of all gly-
cans) were found in this rhPRG4. The glycosylation pattern of
rhPRG4 is similar to what has been reported for CHO cell O-
glycosylation with an abundance of core 1 structures, parti-
cularly the linear monosialylated NeuAca2-3Galb1-3GalNAc
structure (37).
Glycoproteomics reveal location of Tn-antigens, sialyl-Tn,
and core 1 structures both within and outside the rhPRG4
mucin domain
We next performed a glycoproteomics study of rhPRG4
(with and without partial deglycosylation) to identify glycosyla-
ted aa sites and compared the results with glycosites previously
reported for native human lubricin from pooled SF from
OA and rheumatoid arthritis (RA) patients (38). In all, we
detected 318 glycopeptides from rhPRG4 covering 172 gly-
cosylated Ser/Thr sites, the monosaccharide compositions
consistent with core 1 type O-glycans GalNAca1- (Tn-anti-
gen), Galb1-3GalNAca1- (T-antigen), NeuAca2-3Galb1-
3GalNAca1- (sialyl-T), and NeuAca2-3Galb1-3(NeuAca2-
6)GalNAca1- (disialylated T). The results are summarized in
Fig. 2 and in Table S2. Glycopeptide coverage in rhPRG4 was
found to be similar to native human lubricin, with the major-
ity of the glycopeptides originating from the Ser/Thr-rich
mucin domain (aa 232–1056, Fig. 2A). Site specificity over-
lapped well with native lubricin and within the mucin do-
main (Fig. 2, B and C and Fig. S1). 83 sites were detected in
rhPRG4, which had not previously been identified in native
lubricin (Fig. 2B). The majority of the glycopeptides con-
tained 1–3 glycans, although up to five glycosylation sites
were detected on one peptide (TTPETTTAAPK, aa sequence
position 926–936). Glycopeptides generated after partial
deglycosylation revealed additional site-specific information,
enabling the detection of larger glycopeptides in the size range
of 10–20 aa:s. In all, 31 additional glycosylated Ser/Thr were
identified after partial deglycosylation (Table S2). Approxi-
mately 77% (132 of the 172) of the glycosylated Ser/Thr were
found in peptides originating from themucin-like repeat region
(aa 348–855, Fig. 2A) of rhPRG4. The most abundant aa
sequence in this region was the EPAPTTPK, repeated 17 times
in the molecule. 13 EPAPTTPK-derived glycopeptides were
detected and glycosylated on either or both Thr residues (Table
S2). We found 19 glycosylation sites in the N-terminal region
(aa 125–347) and 26 in the C-terminal region (aa 1057–1404).
Most of these sites (16 and 25 sites from the N- and C-terminal
regions, respectively) were found in the nonrepeat regions in
the STP-rich domain flanking the mucin domain 348–1057
(Fig. S1). The most intense glycopeptides identified in rhPRG4
correspond well with those identified from pooled SF from
patients with RA and OA. The main difference was that in
regions with clustered Thr and to some extent also Ser, we usu-
ally found that more sites were positively identified in rhPRG4
compared with native lubricin.
Glycoproteomics of SF lubricin from OA patients
Because previous glycopeptide analysis was performed on
pooled SF samples (38), we pursuedmore sensitiveMS analyses
using higher-energy collisional dissociation (HCD) MS and
MS/MS, addressing the characterization of SF lubricin glyco-
peptides from two individual OA patients. This approach re-
vealed 171 and 158 lubricin-derived glycopeptides from the
two patients, respectively, and the full glycopeptide list is
found in Table S2. Glycopeptide coverage did largely match
what was found in the samples derived from rhPRG4 and our
previous study of pooled native lubricin from OA and RA
patients (Fig. 2A and Table S2), suggesting that many glycosy-
lation sites coincide.
To compare SF lubricin and rhPRG4 glycopeptide analyses,















































































Figure 1. MRM analyses ofO-glycans from SF and recombinant lubricin.
A, relative quantification byMRM of releasedO-glycans from synovial lubricin
purified from control and OA individuals. Relative quantification comparison
of OA patients (n = 7, red) and control individuals (n = 7, blue) released gly-
cans from SF lubricin showing core 1 and core 2 O-glycans, with the most
dominant structures being the unmodified andmonosialylated core 1. Graph
shows individual data points, average, and S.E. *p 0.05. Statistical analyses,
two-tailed Student’s t tests, were carried out to compare the normal and OA
synovial lubricin glycan relative abundances. Symbol key is according to the
Symbol Nomenclature for Glycans. B, example of extracted ion chromato-
gram of O-glycans from lubricin from a control individual. Inset is zoomed in
area of low intensity MRM transitions from 8.5–13.5 min. C, relative quantifi-
cation byMRM of releasedO-glycans from rhPRG4 showing only core 1 struc-
tures and an abundance of the linear monosialylated structure. Data are from
two batches, each repeated in duplicate. Graph shows individual data points,
average, and S.E. D, example of extracted ion chromatogram of rPRG4. For
key of symbols, see (A).
Galectin-3 and lubricin
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‘VLAKPTPK’ glycoforms detected with LC/MS 
H
E
Figure 2. O-linked glycosite map of rhPRG4 compared with synovial lubricin. A, glycopeptides from recombinant (rhPRG4) (this report) and SF lubricin
pooled from five patients with OA and RA (this report and Ali et al.) were analyzed with LC-MS with CID and ETD fragmentation before and after partial degly-
cosylation with sialidase and O-glycanase. B, total number of O-glycosylation sites confirmed by ETD in rhPRG4 and from previous analysis of SF lubricin from
pooled RA and OA patients on whole lubricin and (C) in the repeat region (aa 348–855) (D). Inserted table shows the glycovariant of the glycopeptide
VLAKPTPK found in SF lubricin and in rhPRG4. E–H, examples MS/MS of the glycopeptides variants of VLAKPTPK from lubricin identified from rhPRG4 (ETD)
and from an OA patient (HCD);m/z at 406.90 (31) from rhPRG4 interpreted as a T-antigen (Galb1-3GalNAca1-) (E);m/z at 503.93 (31) from rhPRG4 interpreted
as sialyl-T (NeuAca2-3Galb1-3GalNAca1-) (F); m/z 474.59 (31) interpreted as a core 2 glycan (Galb1-3(GlcNAcb1–6)GalNAca1-) from an OA patient (G); m/z
649.83 (21) interpreted as a sulfated core 1 glycan (HSO31 Galb1-3GalNAca1-) from an OA patient (H). For key of symbols, see Fig. 1A.
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Fig. 2D) will be used as an example. Seven VLAKPTPK gly-
copeptides were identified in each of the two sample types. This
peptide backbone sequence contains only one potentialO-glyco-
sylation site (T). In addition to simple core 1 structures identified
in rhPRG4 (Fig. 2, E and F), we also detected more exotic type
O–linked glycans attached to native lubricin. Examples of two of
these spectra are shown in Fig. 2, G and H. Both spectra were
dominated by amajor fragment ion corresponding to the peptide
backbone without its glycosylation (m/z 853.55). The core 2 gly-
copeptide variant of this glycopeptide was identified containing
two N-acetylhexosamine (HexNAc) and one hexose (Hex),
consistent with a (Galb1-3(GlcNAcb1–6)GalNAca1-) core 2
sequence. Low molecular oxonium ions at m/z 138, 144, 168,
186, and 204 originated from fragmentation of monosaccharide
residues and were diagnostic for glycan containing peptides. The
other example from SF lubricin is a VLAKPTPK glycopeptide
with a T-antigen with an associated sulfate residue (Fig. 2H).
We have previously shown that sulfated core 1 O-glycans exist
on SF lubricin both as 3-linked and 6-linked sulfates to the non-
reducing end Gal residue but also to the 6-position of the reduc-
ing end GalNAc residue (39). The diagnostic glycan oxonium
ions at m/z 204, 366, and 446 were glycan fragment ions
consisting of HexNAc, HexNAc-Hex, and HexNAc-Hex 1
sulfate, respectively. This peptide example illustrates that
sulfoglycopeptides can successfully be identified among
other glycopeptides in positive ion mode without targeted
approaches that have been suggested (40).
One N-glycosylated site was found on lubricin from both
recombinant and OA patient–derived lubricin at Asn-1159.
The two dominant glycoforms found in both samples were of
high mannose–type Hex5HexNAc2 and Hex6HexNAc2, respec-
tively. Annotated HCD and collision-induced fragmentation
(CID) spectra of these are displayed in Fig. S2 and Fig. S3.
Lubricin glycosylation identified using lectin ELISA
We investigated the use of lectins to study lubricin glycosyla-
tion based on the knowledge generated by glycomics and glyco-
proteomics.With glycomics, singly and doubly sialylated core 1
and core 2 structures were readily detected. Detection of Tn-
antigens on lubricin was based on glycoproteomic analysis. We
selected peanut agglutinin (PNA) (Galb1-3GalNAca1-), galec-
tin-3 (Galb-1GlcNAcb1-), Sambucus nigra agglutinin (SNA)
(NeuAca2-6GalNAca1-), and Helix aspersa agglutinin (HAA)
(GalNAca1-) based on detected lubricin oligosaccharides. We
used them in a sandwich ELISA using anti-lubricin 9G3 anti-
body. Additional lectins included Aleuria aurantia lectin (AAL)
(Fuca1-3/6) and L-selectin (sialyl 6-sulfo Lewis X) because it
has been shown that lubricin contains both fucosylated and sul-
fated structures (14). Our lectin sandwich ELISA was used to
probe the glycosylation of lubricin from OA patients’ and con-
trols’ SF (Fig. S4). We found that lectins, corresponding to less-
abundant structures detected by MS glycomics, varied the
most. For galectin-3, AAL, and L-selectin, the percents coeffi-
cient of variation (CV) were found to be 147% (OA patients)/
141% (controls) and 78% (OA patients)/120% (controls),
respectively. For SNA and PNA, the percents CV varied less:
36% (OA patients)/74% (controls) and 25% (OA patients)/40%
(controls), respectively. HAA lectin binding showed the least
variation, with percents CV of 37% and 34% in controls and OA
patients, respectively. No significant differences were detected
in the ELISA response between different glycoforms of SF
lubricin (n = 6 controls, n = 8OA patients; Fig. S4).
The combined conclusion from MS glycomics, glycoproteo-
mics, and lectin sandwich ELISA is that Tn-antigen, T-antigen,
and T-antigen’s sialylated version are by far the dominating
structures on lubricin, and that pathologic OA changes mani-
fest as lowered level of core-2 structures and increased level of
unsialylated Tn- and T-antigens.
Galectin-3 binding to lubricin and endogenous galectin-3 in
SF
We further investigated the ability of lubricin to bind galec-
tin-3. SF from 30 OA patients was probed with recombinant
galectin-3 using the lectin ELISA assay. We found that the
level of galectin-3 active lubricin present in SF varied ;1–2
orders of magnitude between these individuals (Fig. 3A).
Figure 3. Lubricin O-glycans and Galectin-3. A, recombinant galectin-3 binding to OA lubricin. Galectin-3 binding to lubricin from SF of late-stage OA
patients (n = 30) was measured using a sandwich lectin ELISA assay (see “Experimental procedures”). Treatment of OA SF (n = 8) with periodic acid shows that
the binding to galectin-3 was glycosylation dependent. B, increase of extended structures binding to galectin-3 relative to unextended GalNAca1-Ser/Thr
(measured by HAA lectin) present on lubricin from late-stage OA patients (n = 12, red) and control SF (n = 13, blue). Ratio of the absorbances at 450 nm were
calculated for each sample. Samples were measured in duplicates. C, endogenous galectin-3 in SF. Galectin-3 concentrations in SF were measured in samples
from 23 late-stage OA patients (red) and 14 controls (blue). Data in this figure is represented as median with interquartile range, and significant difference was
calculated by nonparametric Mann-Whitney test with ***p, 0.001.
Galectin-3 and lubricin



























Periodate treatment, which destroys the glycans, abolished the
binding, proving that the interaction was purely dependent on
glycosylation (Fig. 3A). Because our glycoproteomic analysis
showed that the Tn-antigen was present on lubricin, we investi-
gated whether there was a difference between OA patients and
controls in how much of this biosynthetic precursor was
further processed into core 2. The relative proportion of galec-
tin-3 binding (core 2) against the binding to the HAA lectin
(Tn-antigen) showed that the glycosylation of lubricin from
late-stage OA (n = 12) compared with the controls (n = 13) had
changed. The relative binding to galectin-3 compared with
HAA decreased by almost a factor of 2 in OA patients (p ,
0.001, Fig. 3B). These data corroborate the shortening of gly-
cans in OA observed by glycomics where core 2 glycans were
decreased relative to T-antigen (Fig. 1). Here we show by using
HAA that core 2 glycans, measured by galectin-3, were de-
creased relative to the truncated Tn-antigen (Fig. 3B). Together
this suggests that lubricin carried fewer core 2 glycans in OA
on amolecular basis.
Because galectin-3 has been reported to be present in SF
(41), we speculated that the difference in binding of galectin-3
to lubricin may have functional consequences. Hence, we went
on to also establish the level of SF galectin-3 in our sample set.
The data generated showed a significant decrease (50%) in the
total amount of endogenous galectin-3 in SF of the late-stage
OA (n = 23) compared with controls (n = 14) (Fig. 3C). Our
data suggest that both the level of galectin-3 and its ability to
bind SF lubricin are altered as a consequence of OA.
Galectin-3 and core 2 glycosylation
A potential functional impact of the alteredOA glycosylation
identified was investigated further. Lubricin glycans are essen-
tial for several critical properties of lubricin involving lubrica-
tion and binding properties and have been suggested to bind to
galectin-3 to improve lubrication of the joint via the abundant
T-antigen epitopes (Galb1-3GalNAc1a-) (33). However, we
observed decreased lubricin binding to galectin-3 in OA in
Figure 4. Galectin-3 binding to core 2 glycans. To display the difference of galectin-3 binding between core 1 and core 2, 1 mg of PSGL-1/mIgG2b (with
core 1 glycans) (lane 1) and PSGL-1/mIgG2b 1 GCNT1 transferase (with core 2 glycans) (lane 2), immunoprecipitated from CHO tissue culture, were loaded,
separated, blotted, and subsequently stained with biotinylated galectin-3 (panel A). Below the lanes, representative oligosaccharide cartoons show dominant
O-glycans found on the two PSGL-1/mIgG2b glycoforms as described elsewhere. PSGL-1/mIgG2b monomers were detected in the area between 268–460
kDa, showing intense staining of the PSGL-1/mIgG2b expressed in CHO cells transfected with the GCNT1 transferase but less stainingwith the PSGL-1/mIgG2b
with core 1 glycans. The same samples (50 ng each) were also separated, blotted, and stained by anti-PSGL1 (panel B) and anti-mouse IgG (mIgG) (panel C) anti-
bodies in separate experiments, confirming similar concentration of the two constructs. The figure represents a typical result performed under optimized con-
ditions from a selection of three repeats. For control, samples (1 mg each) loaded in the same order were separated and gels were stained for sugars using Pro-
Q Emerald (panel D) and for proteins using Ruby (panel E). The gels include a molecular weight marker lane (M) identifying the PSGL-1/mIgG2b proteins with a
molecular mass.180 kDa. F, SPR experiment showing binding of bovine lubricin (bPRG4) to recombinant galectin-3, whereas rhPRG4 did not bind. Inserted
are cartoons showing prominent O-glycans on the two proteins, with symbol key displayed in Fig. 1A. G, calculation of binding constant of bPRG4/galectin-3
from SPR based onmolecular mass of bPRG4 estimated to 220 kDa.
Galectin-3 and lubricin



























parallel with an increase of this glycan on OA lubricin, which
led us to test the hypothesis that the lubricin–galectin-3 inter-
action may be mediated by epitopes presented on extended
core 2 glycans.
To address whether core 2 glycans compared with the sim-
pler core 1 glycans were responsible for the galectin-3 binding,
we used recombinant glycotechnology. We used a CHO cell
line stably transfected by the human core 2 GlcNAcb1–6 glyco-
syltransferase shown to convert the native CHO cell core 1 gly-
cosylation into sialylated core 2 with over 90% efficiency (42). A
reporter O-linked mucin-type glycoprotein (PSGL-1/mIgG2b)
expressed in these cells was shown to be able to bind recombi-
nant galectin-3 (Fig. 4, A–E). Without transfection of the
glycosyltransferase, only low binding to PSGL-1/mIgG2b was
observed (Fig. 4A, first lane). This demonstrated that core 2
type oligosaccharides are key for recognition by galectin-3.
Further support for this was provided by surface plasmon
resonance (SPR). The core 1 recombinant version of lubricin
CHO-rhPRG4 glycosylation was not able to bind galectin-3,
whereas the positive control of lubricin isolated from bovine
chondrocyte cell culture (bPRG4) with both core 1 and core 2
glycosylation (Table S3) displayed significant interaction with
galectin-3 with a KD calculated to 3.8 mM (Fig. 4, F and G). The
data together indicate that the avidity of the multimeric galec-
tin-3 relies on numerous epitopes within lubricin and its mucin
domain. The PSGL-1/mIgG2b O-linked oligosaccharides gen-
erated after transfection of CHO cells using human core 2
GlcNAcb1–6 glycosyltransferase terminate with sialic acid af-
ter adding a LacNAc unit to the natively expressed core 1 struc-
tures (42). This is also the type of core 2 structure found on SF
lubricin (36).
Discussion
Altered glycosylation and lubricin level in OA
The data from lectin ELISA suggested that the glycosylation
in late-stage OA had changed compared with controls (Fig. 3B).
However, using only two lectins (HAA and galectin-3) to dis-
play this change makes it difficult to pinpoint the overall nature
of this glycosylation change. For this, the MRM semi-quantifi-
cation of O-glycans from SF lubricin gave more information,
demonstrating a 10% increase of the truncated unsialylated
core 1 structures (Galb1-3GalNAca1-) in late-stage OA,
accompanied by a decrease of low-abundance core 2 glycans
(Fig. 1A). This MRM result and the data from the lectin ELISA
suggest that the Tn-antigen (GalNAca1-) is also increased at
the expense of larger structures including both core 1 and core
2. However, because the lectin ELISA is limited in its ability to
quantify the level of lubricin in the sample, the absolute levels
of the various Tn-antigen, core 1, and/or core 2 structures in
lubricin are difficult to appreciate. The fact that glycosylation
of lubricin is changing makes the quantification of lubricin dif-
ficult. Current methods for determining lubricin concentration
are often based on antibodies targeting the changing mucin
domain and/or lectins for detection or capturing (43). Hence,
the glycosylation change of lubricin may have contributed to
the confusion in the literature, where the level of SF lubricin
has been shown to be increased, decreased, or unaltered in
OA (43).
Functional implications of lubricin glycosylation
It has been demonstrated previously that the high number of
negatively charged sialic acid residues located within the center
of the lubricin molecule with positively charged lysine- and ar-
ginine-rich N- and C- termini creates the amphoteric nature of
the lubricin glycoprotein (38). The glycosylation, along with the
organization of sialic acid within the molecule, has been associ-
ated with the effective lubrication property of lubricin (38, 44).
This organization creates a central hydration shell and spar-
ingly glycosylated N- and C- termini available to bind to other
cartilage proteins including COMP and collagen II. An effective
boundary lubrication model with firm adherence to the articu-
lar cartilage surface of glyco-mediated lubrication can be pro-
posed (18, 19, 38). The reduction in charged residues in OA
observed in this report may affect the overall charge and poten-
tially the lubricating properties of the lubricinmolecule in OA.
Our data on SF lubricinO-glycan truncation in OA also bear
implications on binding to galectin-3. Previous studies have
indicated that galectin-3 exhibits only weak affinity to O-glyco-
proteins and O-glycopeptides expressing single core 1 O-gly-
cans (Galb1-3GalNAca1- or NeuAca2-3Galb1-3GalNAca1-)
(35, 45). Instead, internal LacNAc glycans on extended oligo-
saccharides have been described to be the high-affinity ligands
for galectin-3 (46). Here, we suggest that interaction between
galectin-3 and native lubricin is mediated by short single Lac-
NAc extended core 2 structures. Indeed, expression of the core
2b-1,6-N-acetylglucosaminyltransferase (C2GnT) responsible
for biosynthesis of core 2 O-glycans has been shown to enable
binding of galectin-3 to bladder tumor cells (47).
rhPRG4 has been shown to have similar lubrication proper-
ties as bPRG4 in vitro (48). Hence, the proposed galectin-3
binding to lubricin (33) is likely to only fine-tune the boundary-
lubricating glycosurface of the joint.
In regard to galectin-3 levels in SF, it has also been shown
that patients with RA have increased SF galectin-3 (41, 49, 50),
whereas the literature is less conclusive about the levels in OA.
Our data indicate that compared with normal SF, the galectin-3
levels are diminished in late-stage OA. Our hypothesis suggests
that an altered ability of OA lubricin to bind galectin-3 together
with decreased galectin-3 levels in OAmay contribute to desta-
bilization of boundary lubrication and contribute to joint deg-
radation (Fig. 5). However, this notion needs to be reconciled
with results from a large animal OA model where CHO cell–
derived rhPRG4 was shown to retard cartilage degeneration
(26). Our data show that glycomic and glycoproteomic analyses
provide the ability to unravel the multifaceted enigmatic OA
etiology and pathology. Of note, this is even without taking into
account that cartilage harbors the largest volume of glycans
(keratan sulfate and chondroitin sulfate) in the body.
Glycomap of native lubricin
A previous map of native lubricin was performed on tryptic
and Lys-C–digested O-glycopeptides of intact and partially
deglycosylated glycopeptides from a pooled sample (38). Here,
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we included sites identified on native lubricin from individual
patients using a fast-scanning Orbitrap mass spectrometer
to make the glycosite map more complete. Because of fast
scanning and sensitivity, low-abundance glycoforms could be
selected for MS/MS without any prefractionation and multi-
ple digestion strategies. We identified 171 and 158 glycopep-
tides from the two lubricin tryptic digests from OA patients,
many of which had not been detected before. This sensitive
approach allowed the first detection of a sulfatedO-glycopep-
tide from lubricin (Fig. 2) and evidence for an N-glycosylation
site on lubricin (Fig. S1 and Fig. S2). In our previous study of
pooled lubricin from bothOA and RA patients, we reported 185
O-glycopeptides, yet after excluding those glycopeptides that
were enzymatically deglycosylated, this number dropped down
to 122. However, partial deglycosylationmay still need to be car-
ried out to identify sites within the mucin domain. For example,
the glycopeptides with aa sequences EPAPTTTK, KPAPTTPK,
and SAPTTPK, which are found repeated eight, four, and four
times in the protein, respectively, were either not detected or
poorly represented in the analyses of individual OA patients but
were found in both rhPRG4 and in our previous study after
deglycosylation. In this paper we identified eight sites in native
lubricin in addition to already recorded sites (38).
The rhPRG4 molecule
The analyses here showed the detailed glycomic and glyco-
proteomic analyses of the heavily O-glycosylated CHO
expressed protein lubricin giving glycosite-specific informa-
tion and detailed O-glycan identification and quantification.
Obtained glycopeptides from rhPRG4 digested with trypsin
or Lys-C were analyzed with LC–MS/MS and CID/electron-
transfer dissociation (ETD) fragmentation before and after
partial deglycosylation. In total, 172 glycosylation sites (Ser/
Thr) were identified compared with the previously reported
107 for native lubricin obtained with the same approach (38).
The majority of the glycosylation sites of rhPRG4 were found
on peptides that were repeated between 2–17 times in lubri-
cin mucin domain. The dominant glycans found corresponded
to simple core 1 type O-glycosylation, whereas native lubricin
also contained core 2. The difference in glycosylation sites is
probably a reflection of differences in specificity and level of
GalNAca1-polypeptide transferases. Human synovial cells are
dominated by T1-, T2-, T5-, and T15-GalNAc transferase (38),
whereas CHO cell glycosylation predominantly expresses the
hamster equivalent of human T2-transferase (51). We may also
attribute differences in detected glycosylation sites to the
increased glycosylation complexity of native lubricin compared
with rhPRG4. In addition, the decreased complexity of glycans
in rhPRG4would cause decreased glycopeptide diversity leading
to increased molar amounts and detectability of individual gly-
copeptides. In addition, the differences in the level of glycosyla-
tion could also contribute to differences in efficiency in the
digestion of themucin domain.
Our glycoproteomic data shows that glycans on rhPRG4 are
positioned in the same central domain as in synovial lubricin.
Lubricin (both native and recombinant) contains one of the
largest mucin domains where glycosylation sites have been
mapped. In synovial lubricin, 37% of Ser/Thr residues were gly-
cosylated in the STP-rich region aa 232–1056, whereas in
rhPRG4, 60% of Ser/Thr residues were found to be glycosyla-
ted. However, we need to state that the site localization relies
on positive identification, so absence of detection does not
mean that remaining sites are not glycosylated.
Differences in glycosylation between native lubricin and
rhPRG4 invoke a question about the impact of glycosylation on
the N- and C- termini involved in interactions. Lubricin has,
for example, been shown to bind noncovalently to COMP
within aa 105–202 and covalently by specific disulfide bonds
between aa 64–86 (19). Glycosylation sites were identified just
adjacent to or within these regions (Table S2).
The O-glycomic data shows that rhPRG4 glycosylation is
dominated by the linear monosialylated core 1 structure, simi-
lar to native synovial lubricin. rhPRG4, as such, contains the
main molecular functions attributed to native lubricin. Although
there is a reduction in disialylated structures, there is an overall
increase in sialylation, giving the rhPRG4 molecule a more nega-
tively charged central domain similar to SF lubricin from control
individuals rather than lubricin found in OA patients (Fig. 1).
However, rhPRG4 does have a more limited range of glycans
with no core 2 or extended core 1 structures present. These struc-
tures may be involved in other glycan-glycan interactions with
the ECM, interacting with galectin-3, or involved in the immune
system (14). Overall, it is clear that both the type and the specific
pattern of glycosylation are quality attributes to the lubrication
and binding function of this very heavily glycosylated protein.
The data indicate that glyco-design could help to further improve
functionality of rhPRG4. Active modulation of O-linked glycosy-
lation for biologics is an unexplored area. As of yet, it is unknown
whether these changes of lubricin in SF are deleterious to the
function of the molecule in vivo. It is also unknown whether
Figure 5. Proposed model for the organization of lubricin and galectin-
3 in the superficial articular layer in normal joint and in OA. A, in the nor-
mal joint, synovial lubricin mostly secreted by synoviocytes and chondro-
cytes adheres to the cartilage surface and contains a significant amount of
LacNAc epitopes (represented as linked blue square and yellow circle) that
allows galectin-3 interaction and crosslinking of lubricin molecules. B, in OA,
lubricin with changed glycosylation because of an altered glycosylation ma-
chinery in synoviocytes and/or chondrocytes is still capable of adhering to
the cartilage and provide boundary lubrication, but the decreased amount of
galectin-3 and its decreased interaction with lubricin with lower amount of
LacNAc destabilize the glycosylated articular surface.
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alterations in lubricin glycosylation are a biological response to
OA conditions, where the change in negative charges is an
attempt to alter the lubricating function of the expressed lubricin.
This could be because of a metabolic response to simplify and
maintain expression of a less energetically expensive molecule in
the face of exogenous stress or to potentiate downstream signal-
ing through altered galectin-3 release. Given the complexity of
timing and severity of effects on biological functions within the
OA joint, it can be summarized that there are important altera-
tions in the amount and type of glycosylation in a critical lubricat-
ing system and that functional and inflammatory aspects of the
disease are likely regulated by the attached sugars, all of which
warrant additional research and focus for heretofore unexplored
pathogenicmechanisms in a very serious disease.
Experimental procedures
Samples, human tissues, and cells
rhPRG4 expressed from CHO cells was purified as described
elsewhere (2, 52). bPRG4 was purified using CsCl gradient and
anion exchange chromatography, and purity was confirmed
with SDS-PAGE/Western blotting and MS as described else-
where (53). Recombinant galectin-3 used in all experiments
unless stated elsewise was provided by Professor Haakon Leffler
(Lund University, Sweden). SF samples from OA patients that
were scheduled for total knee replacement (n = 2, 76 and 84
years old) for the glycopeptide analyses were collected during
therapeutic joint aspiration at Sahlgrenska University Hospital
(Gothenburg, Sweden). SF samples for O-glycomic analyses
were collected from patients with symptomatic chronic knee
OA requiring aspiration (OA patients n = 7, average age 56
years, range 34–72 years). The patients for O-glycomics were
diagnosed as having knee OA by two sports medicine physi-
cians following a review of the patients’ symptoms, a physical
examination, and plain-film radiography. Control samples (n =
7, average age 56 years, range 31–72 years old) were collected
postmortem within 4 h. The samples were collected from the
knee by aspiration, clarified (3,0003 g for 30 min at 4 °C), and
stored at 280 °C. SF samples for galectin-3 studies were
obtained from late-stage OA patients prior to total knee
replacement, mean age 69 years (n = 30, range 58–78 years old)
at Sahlgrenska University Hospital and at Danderyd Hospital
(Stockholm, Sweden). Control SF samples were collected as
described above, mean age 65 years (n = 18, range 47–76 years
old). All samples were collected after written consent from
patients and controls, and the procedure was approved by the
Conjoint Health Research Ethics Board of the University of
Calgary (REB15–0880) or by the Regional Ethical Review Board
in Gothenburg (ethical application 172-15); the study abided by
the Declaration of Helsinki principles.
Release and LC-MRM analysis of oligosaccharides from
rhPRG4 and synovial lubricin
Lubricin from SF of OA patients (n = 7) and controls (n = 7)
were isolated via a multistage process. The same amount of SF
(500 ml) was used for each sample to allow for consistent MRM
analyses on the resultant released glycans. The acidic SF pro-
teins were isolated from SF samples by diethylaminoethyl chro-
matography as previously described (54). The samples were
reduced and alkylated and separated by SDS-PAGE using
NuPAGE 3–8%Tris acetate gels to allow isolation of the lubricin.
The gels were transferred to PVDF membrane by semi-dry
transfer blotting, stained with Alcian blue, and destained with
methanol (55). The lubricin band was excised from each sample
individually and the O-linked oligosaccharides were released by
reductive b-elimination (50 mM sodium hydroxide and 0.50 M
sodium borohydride) overnight, followed by cleanup on cation
exchange columns (AG50WX8, Bio-Rad) in C18-ZipTips (Milli-
pore) (56). Oligosaccharides with reducing end (alditols) were
separated on porous graphitized carbon columns (5-mm par-
ticles, Hypercarb, Thermo Fisher Scientific) prepared in-house,
with the dimensions of 10 cm (length) and 250mm (inner diame-
ter). The gradient, after 5 min of 98% solvent A (10 mM ammo-
nium bicarbonate), increased with solvent B (80% acetonitrile in
10 mM ammonium bicarbonate) from 2–45% in 41 min, then to
95% solvent B in 4 min. Solvent B (95%) was held for 5 min
before re-equilibration at 98% A for 35 min. The flow rate was
kept at a constant 10 ml/min using an Ekspert MicroLC 200
HPLC system (Eksigent, AB Sciex, Framingham,MA, USA).
The oligosaccharides were analyzed on a QTRAP 6500 ESI-
triple quadrupole-linear ion trap hybrid mass spectrometer
(AB Sciex) in negative-ion, high-mass mode. A turbo V ion
source was used with a 25-mm electrode. An ion spray voltage
of 4,200 was used. Collision energy, declustering potential, and
collision cell exit potential were optimized for each transition.
The final method included transitions to quantify and identify
all 24 identified structures on lubricin. All transition informa-
tion is published in detail (36).
Relative quantitation and statistical analyses of MRM data
MultiQuant 3.0 (Sciex) was used for MRM peak integration.
Area under the curve was determined for all structures and
combined for total glycan abundance. Each glycanwas then rep-
resented as a relative percentage of the total glycan abundance.
Statistical analyses, two-tailed t tests, were carried out to com-
pare the normal and OA synovial lubricin glycan relative abun-
dances. GraphPad Prism 5.0 for windows (GraphPad Software)
was used to carry out statistical analyses and to draw graphs.
Release and analysis of oligosaccharides from bPRG4
Oligosaccharides from bPRG4 (60 mg) were released in 1.0 M
NaBH4/0.10 M NaOH at 50 °C (100 ml) overnight, followed by
neutralization with concentrated acetic acid, and desalted with
150 ml of cation exchange media AG50WX8 in a 100-mg C18
Strata SPE column (Phenomenex). The glycans were analyzed
with LC-MS and MS/MS using porous graphitized carbon
chromatography as described above, connected to an LTQ XL
ion trap mass spectrometer (Thermo Fisher Scientific) as
described elsewhere (14). Structures were assigned based on
MS/MS fragmentation by comparison with fragment spectra
available in UniCarb-DB (57) and -DR (58) and by manual
interpretation aided by using GlycoWorkbench software (59,
60). Assignment of structural data based on MS interpretation
was recorded according to reporting guidelines (MIRAGE) for
glycomics sample preparation (61) andMS (58, 62).
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Purification, digestion, and LC-MS analysis of glycopeptides from
rhPRG4
Aliquots of purified proteins from rhPRG4 were treated with
or without glycosidases (sialidase A and/or O-glycanase), fol-
lowed by SDS-PAGE (3–8% Tris acetate NuPAGE gels) (Invitro-
gen, Stockholm, Sweden) and tryptic digestion, or digested in-
solution with either trypsin or Lys-C as described previously
(38). The peptides were desalted with C18 stagetips (63) followed
by glycopeptide enrichment using HILIC tips prepared in-house
using cottonwool (38, 64) or commercially available columns
(Thermo Fisher Scientific). For LC-MS analyses, C18 columns
were prepared in-house and used with formic acid in acetonitrile
gradients. The glycopeptides were analyzed on an LTQOrbitrap
XLmass spectrometer (Thermo Fisher Scientific) equipped with
CID and ETD fragmentation as described (38).
Purification, digestion, and LC-MS analysis of glycopeptides
from SF lubricin from two OA patients
SF lubricin from patients with OA was purified as described
elsewhere (54). Briefly, SF (0.5 ml) was subjected to anion
exchange chromatography and the acidic protein fraction was
collected and precipitated in ethanol. The acidic proteins were
reduced in 10 mM DTT (70 °C, 1 h) and alkylated in 50 mM io-
doacetamide for 30 min at room temperature in the dark. Salts
were removed and buffer was exchanged to 50 mM ammonium
bicarbonate (Sigma-Aldrich) using 30-kDa cutoff filters (Merck
Millipore), followed by lyophilization. The reduced and alky-
lated protein-containing gel bands were digested with trypsin,
and the peptides were extracted and desalted with StageTip
C18 columns (63). The peptides were separated using in-house
packed C18 columns at 200 nl/min using a 120-min gradient of
5–40% buffer B (A: 0.1% formic acid, B: 0.1% formic acid, 80%
acetonitrile). The column was connected to an Easy-nLC 1000
system (Thermo Fisher Scientific), a nano-electrospray ion
source, and a Q Exactive Hybrid Quadrupole-Orbitrap Mass
Spectrometer (Thermo Fisher Scientific). For full-scan MS,
the instrument was scanned at m/z 350–2000, resolution
70,000 (at m/z 200), AGC target 1 3 106, max injection time
120 ms, and dynamic exclusion was auto or 20 s. The 12 most
intense peaks (charge states 2, 3, and 4) were selected for frag-
mentation. For MS/MS, resolution was set to 17,500 (at m/z
200), AGC target to 5 3 105, max injection time 256 ms, and
normalized collision energy = 30 with stepped normalized colli-
sion energy of 25%.
Assignment of lubricin glycopeptides
Peptide searches were performed using Mascot version
2.3.02 against the Swissprot database version 2017-06. Glyco-
peptide searches were carried out using both manual and soft-
ware-assisted interpretation using Byonics (version 2.6.46, Pro-
tein Metrics, San Carlos, CA) against human lubricin (Uniprot
entry Q92954). For Orbitrap XL data (recombinant lubricin),
parameters were set as follows: precursor tolerance 10 ppm;
fragment tolerance 0.5 ppm; enzyme: Lys-C or trypsin, cleavage
before proline included; maximum two missed cleavages; fixed
carbamidomethyl modification of cysteines, variable modifica-
tion: oxidized methionine. For the glycopeptide searches in
Byonics, settings were maximum two glycan modifications per
peptide; glycan compositions: HexNAc(1), HexNAc(1)Hex(1),
HexNAc(1)Hex(1)Sulf(1), HexNAc(1)NeuAc(1), HexNAc(1)
Hex(1)NeuAc(1), HexNAc(1)Hex(1)NeuAc(1)Sulf(1), and Hex-
NAc(1)Hex(1)NeuAc(2). The glycans were all defined as “com-
mon.” For Q Exactive data (native lubricin from OA patients),
parameters were the same except fragment ion tolerance was
set to 10 ppm. In Byonics, the data set was searched against
seven additional glycans of core 2 type: HexNAc(2)Hex(1),
HexNAc(2)Hex(1)Sulf(1), HexNAc(2)Hex(2)Sulf(1), HexNAc
(2)Hex(1)NeuAc(1), HexNAc(2)Hex(2)NeuAc(1), HexNAc(2)
Hex(2)NeuAc(2), and HexNAc(2)Hex(2). Sulfated glycans were
defined as “rare,” the remaining as common. Glycopeptide spec-
tra with a score higher than 200 were considered and validated
manually. For positive identification, at least five b/y ions origi-
nating from the peptide backbone sequence were required, and
all major peaks in the spectra were assigned.
Production of secreted PSGL-1/mIgG2b fusion protein
Mucin-type fusion protein P-selectin glycoprotein ligand-1/
mouse immunoglobulin G2b (PSGL-1/mIgG2b) and human
core 2 b1,6-N-acetylglucosaminyltransferase 1 (C2GnT-1) plas-
mids carrying puromycin and geneticin (G418 sulfate) drug
resistance genes, respectively, were constructed as described
previously (65, 66). PSGL-1/mIgG2b derived from the CP-55
clone containing only core 1 glycans was generated and purified
as previously described (67). The core 2 clone was from a previ-
ous publication generated by transfecting CHO-K1 cells with
cDNA encoding PSGL-1/mIgG2b. This clone was shown to
convert standard CHO-cell core 1 glycosylation into core 2 with
more than 90% efficiency (42). The core 2 clone was cultured in
serum free ProCHO-4medium (Lonza, Basel, Switzerland) sup-
plemented with 2 mM L-glutamine (Invitrogen), 100 units/ml
penicillin, and 100 mg/ml streptomycin (Invitrogen), as well as
selection drugs.
Quantification of PSGL-1/mIgG2b by ELISA
A sandwich ELISA method was used for the quantitative
measurement of PSGL-1/mIgG2b concentrations in superna-
tants. The 96-well ELISA plates (Costar 3590; Corning) were
coated with an affinity-purified polyclonal goat anti-mouse IgG
Fc-specific antibody (Sigma-Aldrich) at a concentration of 10
mg/ml in 50 mM carbonate buffer, pH 9.6, at 4 °C overnight.
The plates were blocked with 1% (w/v) BSA in PBS to minimize
nonspecific binding. This buffer was also used as an antibody
dilution buffer. The plates were sealed and incubated at room
temperature for 2 h. Supernatants were incubated in the 96-
well plate in triplicate for 2 h before incubating with a peroxi-
dase-conjugated anti-mouse IgG Fc-specific antibody (Sigma-
Aldrich) diluted 1:2,000 for 2 h at room temperature. PBS
containing 0.05% (v/v) Tween-20 (Sigma-Aldrich) and 0.15 M
sodium chloride was used as the wash buffer between incuba-
tions. A bound peroxidase-conjugated antibody was visualized
with 3,39,5,59-tetramethylbenzidine dihydrochloride (Sigma-
Aldrich) as a substrate. The color reaction was stopped by the
addition of 2.0 M H2SO4, and the optical density of the samples
was read at a wavelength of 450 nm in a microplate reader
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(Synergy 2, BioTek). The PSGL-1/mIgG2b concentration was
estimated using a dilution series of purified mIgG2b (AbD
Serotec, Oxford, UK) in blocking buffer as a standard.
PSGL-1 constructs analyzed by SDS-PAGE/Western blotting
For SDS-PAGE/Western blotting, PSGL-1/mIgG2b was puri-
fied from clarified supernatants on goat anti-mIgG agarose
beads by rotating at 4 °C overnight. The beads with captured
fusion proteins were washed three times in PBS, resuspended
in 43 SDS sample buffer without reducing agent (Invitrogen),
and incubated at 95 °C for 5 min for protein denaturation. The
samples were analyzed by SDS–PAGE using 3–8% Tris acetate
gradient gels and Tris acetate SDS running buffer (Invitrogen).
Precision protein standard (Hi-Mark, Invitrogen) was applied
as reference for protein molecular weight determination. Sepa-
rated proteins were blotted using iBlot (Invitrogen) onto nitro-
cellulose membranes. The membranes were blocked with 13
carbo-free blocking solution (Vector laboratories), which was
also used for dilution of antibodies and lectins. A mouse anti-
human CD162 was used to detect the N-terminal part of PSGL-
1 (1:1,000 dilution; BD Pharmingen, San Diego, CA, USA) to-
gether with an HRP-conjugated polyclonal goat anti-mouse
IgG (Fab-specific, 1:10,000 dilution; Sigma-Aldrich) used as
secondary antibody. Biotinylated galectin-3 (diluted 1:100) was
used to detect galectin-3 together with streptavidin (diluted
1:10,000; Sigma-Aldrich). Bound antibody and lectins were
visualized by chemiluminescence using the ECL kit according
to the manufacturer’s instructions (GE Healthcare, Uppsala,
Sweden). The presence of glycosylated and nonglycosylated
proteins was assessed by staining of the gels using a glycopro-
tein staining kit and the Ruby stain (Thermo Fisher Scientific),
respectively. Candy Cane markers (Thermo Fisher Scientific)
were used for molecular weight reference. PSGL-1 constructs
from transient transfection of C2GnT-1 of CHO cells (68) were
also subjected to the procedure of SDS-PAGE, blotting, and
staining as described above.
Lectin ELISA of lubricin from SF
SF Lubricin was probed using an in-house sandwich lectin
ELISA method. 96-well Nunc-Immunomaxisorp plates (Thermo
Fisher Scientific) were coated with 1 mg/ml monoclonal anti-
lubricin antibody clone 9G3 against rhPRG4 mucin domain
(Thermo Fisher Scientific) in PBS at 4 °C overnight. After block-
ing with 3% BSA in Tris-buffered saline (TBS)-Tween (TBS, pH
7.4, 1 0.05% Tween-20), the same volume of SF samples (dupli-
cate of each sample) that were pre-diluted 1 in 50 in assay buffer
(1% BSA in TBS-Tween) were loaded (100 ml) and incubated for
90 min. The captured lubricin was incubated with 2 mg/ml
biotinylated HAA (Sigma-Aldrich), PNA (Vector laboratories),
L-selectin (Sigma-Aldrich), AAL (Vector laboratories), SNA (Vec-
tor laboratories), or biotinylated galectin-3 for 1 h, followed by
a 1-h incubation with 0.2 mg/ml HRP-conjugated streptavidin
(Vector Laboratories). The plate was washed three times with
TBS-Tween between each incubation procedure and five times
before the staining step. After staining with 1-StepTM Ultra
TMB-ELISA Substrate Solution (Thermo Fisher Scientific), ab-
sorbance was read at 450 nm. The ratios of the average absorb-
ance of galectin-3 and HAA staining for each individual sample
were calculated to estimate the level of extension of GalNAca1-
Ser/Thr (HAA) into galectin-3 reactive glycans on lubricin. To
test the glycodependency of galectin-3 binding to lubricin, 6 ml of
SF was incubated with 40ml of 1% periodic acid for 1 h on shaker,
and the system was then neutralized with 40 ml TBS for 20 min.
The samples were diluted in assay buffer and subject to protocol
as described above. Statistical evaluation of lectin sandwich
ELISA was conducted as described in Fig. 3 and Fig. S4. Relative
differences between OA and control of galectin-3 binding were
compared using the lectin ELISA absorbance ratio of galectin-3
versusHAA.
Endogenous synovial galectin-3
Endogenous galectin-3 levels in OA and control SF were
measured by the galectin-3 test ELISA kit (BG Medicine)
according to themanufacturer’s instructions. OA samples were
measured in duplicates and control samples were measured
as singlets because of limited amounts of material. Statistical
evaluation of ELISAs were performed by GraphPad Prism 8
(GraphPad Software). Statistically significant differences were
calculated by nonparametric t test using theMann-Whitney test.
SPR
Binding of rhPRG4 and bPRG4 (53) to galectin-3 was
assessed using a Biacore 3 100 SPR instrument (GE Health-
care). Galectin-3 (R&D Systems) was covalently attached to the
CM5 chip by running 50 mg/ml galectin-3 solution in 20 mM
sodium acetate solution at pH 5, giving a response unit of 3,500.
Injection of lubricin was performed as described (69). Lactose
was used as a regeneration buffer after lubricin injections (70).
Data availability
Raw MS data and assigned glycomic structures are avail-
able for synovial lubricin at GPST000100 and for rhPRG4
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